Shuling Wu , Liu Yang , Xiaoyue Bi , Yanjie Lin , Wen Deng , Tingting Jiang , Minghui Li , Yao Xie
{"title":"Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus","authors":"Shuling Wu , Liu Yang , Xiaoyue Bi , Yanjie Lin , Wen Deng , Tingting Jiang , Minghui Li , Yao Xie","doi":"10.1016/j.gande.2022.10.001","DOIUrl":null,"url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide that seriously threatens human health. Chronic infection of hepatitis virus B, C and D is closely related to the occurrence of HCC, about 80% HCC cases are caused by chronic viral hepatitis. Effective antiviral therapy can control liver inflammation, reduce the occurrence of HCC and reduce the recurrence of HCC after surgery treatment. In addition, during chemotherapy such as transarterial chemoembolization (TACE) or hepatic artery infusion chemotherapy (HAIC), targeted therapy and immunotherapy for HCC, antiviral therapy is also needed to prevent hepatitis virus reactivation. Therefore, antiviral therapy plays an important role in the prevention and treatment of HCC.</p></div>","PeriodicalId":100571,"journal":{"name":"Gastroenterology & Endoscopy","volume":"1 1","pages":"Pages 5-10"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology & Endoscopy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949752322000012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide that seriously threatens human health. Chronic infection of hepatitis virus B, C and D is closely related to the occurrence of HCC, about 80% HCC cases are caused by chronic viral hepatitis. Effective antiviral therapy can control liver inflammation, reduce the occurrence of HCC and reduce the recurrence of HCC after surgery treatment. In addition, during chemotherapy such as transarterial chemoembolization (TACE) or hepatic artery infusion chemotherapy (HAIC), targeted therapy and immunotherapy for HCC, antiviral therapy is also needed to prevent hepatitis virus reactivation. Therefore, antiviral therapy plays an important role in the prevention and treatment of HCC.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
